Clinical and laboratory features at presentation of APL secondary to a previous tumor (APL-st) and de novo APL
| . | APL-st . | de novo APL . | P . |
|---|---|---|---|
| Male patients, no. (%) | 17 of 51 (33.3) | 349 of 641 (55) | < .003 |
| Median age, y (range) | 57 (27-76) | 38.9 (1.4-74) | < .05 |
| PS (WHO) III-IV, no. (%) | 12/51 (24) | 24/641 (3.7) | < .005 |
| FAB M3v (hypogranular), no. (%) | 7/51 (14) | 71/565 (13) | NS |
| White blood cells × 109/L, median (range) | 1.4 (0.2-174) | 2.6 (0.3-140) | NS |
| Platelet count × 109/dL, median (range) | 26.5 (2.0-174) | 23.0 (1.0-117) | NS |
| Hemorrhage, no. (%) | 24/51 (47) | 405/641 (65) | < .02 |
| BCR1 | 21 (62) | 273 (56) | NS |
| BCR2 | 3 (9) | 30 (6) | NS |
| BCR3 | 10 (29) | 185 (38) | NS |
| . | APL-st . | de novo APL . | P . |
|---|---|---|---|
| Male patients, no. (%) | 17 of 51 (33.3) | 349 of 641 (55) | < .003 |
| Median age, y (range) | 57 (27-76) | 38.9 (1.4-74) | < .05 |
| PS (WHO) III-IV, no. (%) | 12/51 (24) | 24/641 (3.7) | < .005 |
| FAB M3v (hypogranular), no. (%) | 7/51 (14) | 71/565 (13) | NS |
| White blood cells × 109/L, median (range) | 1.4 (0.2-174) | 2.6 (0.3-140) | NS |
| Platelet count × 109/dL, median (range) | 26.5 (2.0-174) | 23.0 (1.0-117) | NS |
| Hemorrhage, no. (%) | 24/51 (47) | 405/641 (65) | < .02 |
| BCR1 | 21 (62) | 273 (56) | NS |
| BCR2 | 3 (9) | 30 (6) | NS |
| BCR3 | 10 (29) | 185 (38) | NS |
PS indicates performance status as defined by World Health Organization (WHO; information on PS was available for 533 of 641 patients with de novo APL); BCR1, 2, 3, proportional distribution of different types of PML/RARα fusion evaluated in 34 APL-st and 488 de novo APL patients; M3v, variant (hypogranular) cases.